Treg Modulation With CD28 and IL-6 Receptor Antagonists
Public ClinicalTrials.gov record NCT04066114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6 (CTOT-24)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
Study identification
- NCT ID
- NCT04066114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Interventions
- lulizumab pegol Biological
- antithymocyte globulin (rabbit) Biological
- methylprednisolone Drug
- tocilizumab Biological
- Prednisone Drug
- everolimus Drug
- belatacept Biological
- mycophenolate mofetil Drug
- mycophenolic acid Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2019 (Actual)
- Primary completion
- Sep 14, 2023 (Actual)
- Completion
- Sep 14, 2023 (Actual)
- Last update posted
- Sep 24, 2026
2019 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama School of Medicine: Transplantation | Birmingham | Alabama | 35233 | — |
| University of California San Francisco School of Medicine: Transplantation | San Francisco | California | 94143 | — |
| University of Colorado (UC) Health Transplant Center - Anschutz | Aurora | Colorado | 80045 | — |
| Northwestern Memorial Hospital: Transplantation | Chicago | Illinois | 60611 | — |
| University of Nebraska Medical Center: Transplantation | Omaha | Nebraska | 68105 | — |
| Duke University Medical Center: Transplantation | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Foundation: Transplantation | Cleveland | Ohio | 44195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04066114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04066114 live on ClinicalTrials.gov.